We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+19.88%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$1.1B
AUM Growth
+$208M
Cap. Flow
+$30.3M
Cap. Flow %
2.77%
Top 10 Hldgs %
54.38%
Holding
136
New
36
Increased
27
Reduced
26
Closed
32

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$35.5M
2
NVO
Novo Nordisk
NVO
+$19.7M
3
URGN icon
UroGen Pharma
URGN
+$12.9M
4
BMY icon
Bristol-Myers Squibb
BMY
+$12.4M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$10.9M

Top Sells

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$19.7M
2
CELG
Celgene Corp
CELG
+$18.8M
3
ITRN icon
Ituran Location and Control
ITRN
+$14.6M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$11.6M
5
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 56.49%
2 Miscellaneous 34.04%
3 Technology 6.57%
4 Consumer Discretionary 1.18%
5 Industrials 1.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MTEM
126
DELISTED
Molecular Templates, Inc.
MTEM
– –
-26,667
Closed -$1.62M
EPZM
127
DELISTED
Epizyme, Inc
EPZM
– –
-749,502
Closed -$4.62M
SRRA
128
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-6,463
Closed -$341K
TBIO
129
DELISTED
Translate Bio, Inc. Common Stock
TBIO
– –
-309,400
Closed -$2.32M
GWPH
130
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-77,000
Closed -$7.5M
UROV
131
DELISTED
Urovant Sciences Ltd.
UROV
– –
-214,030
Closed -$1.41M
PTLA
132
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-147,000
Closed -$2.87M
MLNT
133
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
– –
-323,373
Closed -$1.28M
DOVA
134
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
– –
-185,000
Closed -$1.4M
ARRY
135
DELISTED
Array Biopharma Inc
ARRY
– –
-125,000
Closed -$1.78M
2 3 4 5
6

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q1 2019 Portfolio in Review

As of Q1 2019, Sphera Funds Management held 136 positions worth $1.1B, up 23% from $887M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sphera Funds Management's Q1 2019 filing shows 36 new, 27 increased, 26 reduced and 32 closed positions. Its largest new stake was Johnson & Johnson: 265,000 shares worth $37M. The largest sale was Viatris, an estimated $19.7M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 62% a quarter earlier, followed by Miscellaneous and Technology.

  • Sphera Funds Management's largest Q1 2019 buy was Johnson & Johnson: 265,000 shares worth $37M.
  • Sphera Funds Management added most to Bristol-Myers Squibb in Q1 2019, an estimated $12.4M increase.
  • Sphera Funds Management's biggest Q1 2019 reduction was Viatris, cutting an estimated $19.7M.
  • Sphera Funds Management fully exited Ituran Location and Control in Q1 2019, selling an estimated $14.6M.
  • Sphera Funds Management's ten largest holdings make up 54% of its $1.1B portfolio in Q1 2019.
  • Sphera Funds Management opened 36 new positions and closed 32 in Q1 2019.
  • Sphera Funds Management's portfolio value rose 23% quarter-over-quarter to $1.1B.

Based on Sphera Funds Management's 13F filing for Q1 2019, filed 15 May 2019.